Skip to content
Disclosery

Aisling Capital Management LP

Follow

13F filer, CIK 1766721, NEW YORK, NY

Aisling Capital Management LP reported $456,446,711 across 14 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-12. Its ten largest share positions make up 99.35% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001766721-25-000006

Period
2025-09-30
Reported value
$456M
Holdings
14
Top 10 weight
99.35%
New
2
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BBOTnew+564,625$6.54M
SRRKnew+77,031$2.87M
NUVBadded+419,650$1.55M
BBIOadded+21,486$1.12M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ELEVATION ONCOLOGY INC COMexited-2,834,910-$1.04M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001766721-25-000006, largest first. % of portfolio is the value over $456,446,710, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,068,125 shares; 2024Q4: 6,068,125 shares; 2025Q1: 6,068,125 shares; 2025Q2: 6,068,125 shares; 2025Q3: 6,089,611 shares 6,089,611$316M69.29%+21,486Timeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,115,352 shares; 2024Q4: 1,115,352 shares; 2025Q1: 615,352 shares; 2025Q2: 615,352 shares; 2025Q3: 615,352 shares 615,352$65.7M14.39%0
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,025,000 shares; 2024Q4: 1,025,000 shares; 2025Q1: 1,025,000 shares; 2025Q2: 1,316,806 shares; 2025Q3: 1,316,806 shares 1,316,806$20.3M4.44%0Timeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,541,009 shares; 2024Q4: 2,541,009 shares; 2025Q1: 2,541,009 shares; 2025Q2: 2,541,009 shares; 2025Q3: 2,960,659 shares 2,960,659$11M2.4%+419,650Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,472,331 shares; 2024Q4: 1,472,331 shares; 2025Q1: 1,472,331 shares; 2025Q2: 1,472,331 shares; 2025Q3: 1,472,331 shares 1,472,331$10.9M2.39%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 568,919 shares; 2024Q4: 568,919 shares; 2025Q1: 568,919 shares; 2025Q2: 568,919 shares; 2025Q3: 568,919 shares 568,919$8.98M1.97%0Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 964,500 shares; 2024Q4: 964,500 shares; 2025Q1: 1,198,418 shares; 2025Q2: 1,198,418 shares; 2025Q3: 1,198,418 shares 1,198,418$6.87M1.5%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 564,625 shares 564,625$6.54M1.43%newTimeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 798,757 shares; 2024Q4: 798,757 shares; 2025Q1: 798,757 shares; 2025Q2: 2,048,757 shares; 2025Q3: 2,048,757 shares 2,048,757$4.14M0.91%0Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 77,031 shares 77,031$2.87M0.63%newTimeline
CALCCALCIMEDICA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 521,114 shares; 2024Q4: 521,114 shares; 2025Q1: 521,114 shares; 2025Q2: 521,114 shares; 2025Q3: 521,114 shares 521,114$1.6M0.35%0Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 434,455 shares; 2024Q4: 434,455 shares; 2025Q1: 434,455 shares; 2025Q2: 434,455 shares; 2025Q3: 434,455 shares 434,455$825K0.18%0Timeline
MRKRMARKER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 314,286 shares; 2024Q4: 325,370 shares; 2025Q1: 325,370 shares; 2025Q2: 325,370 shares; 2025Q3: 325,370 shares 325,370$290K0.06%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 88,607 shares; 2025Q1: 88,607 shares; 2025Q2: 88,607 shares; 2025Q3: 88,607 shares 88,607$244K0.05%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ELEVATION ONCOLOGY INC COMELEVATION ONCOLOGY INC COM2,834,910$1.04Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001766721-25-000006 base2025-11-12acceptance time not in the bulk data set